These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 793489

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunological adjuvants in cancer immunotherapy.
    Baldwin RW.
    Dev Biol Stand; ; 38():3-12. PubMed ID: 344097
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the antitumor effects of a synthetic biopolymer and standard adjuvants.
    Falk RE, Makowka L, Nossal NA, Rotstein LE, Falk JA.
    Surgery; 1980 Jul; 88(1):126-36. PubMed ID: 6992317
    [Abstract] [Full Text] [Related]

  • 8. Active immunotherapy of cancer for minimal residual disease: new trends and new materials.
    Mathé G, Florentin I, Olsson L, Kiger N, Bruley-Rosset M, Orbach-Arbouys S, Schulz JI.
    Prog Exp Tumor Res; 1980 Jul; 25():242-74. PubMed ID: 6986635
    [No Abstract] [Full Text] [Related]

  • 9. Passive immunotherapy of cancer in animals and man.
    Rosenberg SA, Terry WD.
    Adv Cancer Res; 1977 Jul; 25():323-88. PubMed ID: 326003
    [No Abstract] [Full Text] [Related]

  • 10. Immunotherapy of cancer. Present status and future potential.
    Morton DL.
    Cancer; 1972 Dec; 30(6):1647-55. PubMed ID: 4565820
    [No Abstract] [Full Text] [Related]

  • 11. Tum- variants and the detection of tumor-specific transplantation antigens on spontaneous mouse tumors.
    Boon T, van Pel A, Uyttenhove C, Marchand M, Lambotte P.
    Behring Inst Mitt; 1984 May; (74):209-13. PubMed ID: 6332616
    [No Abstract] [Full Text] [Related]

  • 12. Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection.
    Zarling JM, Tevethia SS.
    J Natl Cancer Inst; 1973 Jan; 50(1):149-57. PubMed ID: 4348219
    [No Abstract] [Full Text] [Related]

  • 13. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.
    Young JW, Inaba K.
    J Exp Med; 1996 Jan 01; 183(1):7-11. PubMed ID: 8551246
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Experimental studies on specific active immunotherapy using immune responses of irradiated tumor tissue. 4. Effects of a combined use of a non-specific immunopotentiator, OK-432].
    Imanaka K, Ogawa Y, Gose K, Imajo Y, Kimura S.
    Nihon Gan Chiryo Gakkai Shi; 1982 Aug 20; 17(5):1299-304. PubMed ID: 7153621
    [No Abstract] [Full Text] [Related]

  • 17. Interleukin-1 as an adjuvant for tumor vaccines increases survival in mice.
    McCune C.
    Biotherapy; 1989 Aug 20; 1(4):355-9. PubMed ID: 2701649
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. RNA extracts in tumor immunity. Induction of anti-cancer immunity with RNA.
    Pilch YH, Ramming KP, Deckers PJ.
    Ann N Y Acad Sci; 1973 May 31; 207():409-29. PubMed ID: 4517718
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.